Related Experiment Video

Updated: Aug 22, 2025

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach
06:38

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach

Published on: June 11, 2017

11.4K

Management of Anesthesia and Perioperative Procedures in a Child with Glucose-6-Phosphate Dehydrogenase Deficiency

Ana Cicvarić1,2, Josipa Glavaš Tahtler1,2, Tea Vukoja Vukušić1

  • 1Department of Anesthesiology, Resuscitation, and ICU, Osijek University Hospital, 31000 Osijek, Croatia.

Journal of Clinical Medicine
|November 11, 2022
PubMed

Insights

Patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency are vulnerable to oxidative stress. Sevoflurane anesthesia with sufentanil was safe and effective for managing a child with G6PD deficiency during surgery.

Area of Science:

  • Biochemistry
  • Hematology
  • Anesthesiology

Background:

  • Glucose-6-phosphate dehydrogenase (G6PD) is crucial for red blood cell antioxidant function.
  • G6PD deficiency increases vulnerability to oxidative stressors, potentially causing hemolytic anemia and jaundice.
  • Surgical stress is a significant trigger for hemolysis in G6PD-deficient individuals.

Observation:

  • Anesthetic management aims to minimize stress and monitor for hemolysis during surgery.
  • The case involved a child diagnosed with G6PD deficiency undergoing surgery.
  • Sevoflurane inhalation anesthesia and sufentanil were administered.

Findings:

  • The combination of sevoflurane and sufentanil was found to be safe and effective.
  • No significant hemolysis was observed or reported in the pediatric patient.
  • The anesthetic approach successfully managed the patient's condition.

Implications:

  • This anesthetic strategy may be suitable for pediatric patients with G6PD deficiency.
  • Further research could explore the safety profile of this anesthetic combination in G6PD deficiency.
  • Optimizing anesthetic care is vital for managing oxidative stress in G6PD-deficient patients.

Keywords:
anesthesia managementglucose-6-phosphate dehydrogenase (G6PD)oxidative stressperioperative managementpostoperative monitoring

More Related Videos

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

3.0K
Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
311
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
224
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.1K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
331
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.0K